European journal of preventive cardiology最新文献

{"title":"Sex differences in myocardial infarction care and outcomes: a longitudinal Scottish National Data-Linkage Study.","authors":"Tiberiu A Pana, Mamas A Mamas, Phyo K Myint, Dana K Dawson","doi":"10.1093/eurjpc/zwae333","DOIUrl":"https://doi.org/10.1093/eurjpc/zwae333","url":null,"abstract":"<p><strong>Aims: </strong>We investigate sex disparities in management and outcomes of myocardial infarction (MI) in contemporary practice in Scotland.</p><p><strong>Methods and results: </strong>This was a longitudinal cohort study including all MI admissions aged 45-80 years across Scotland between 2010-2016 and 2:1 age, sex, and general practice-matched general population controls. Participants were followed up until the end of 2021. We analysed in-hospital outcomes (percutaneous coronary intervention, secondary prevention and mortality) using Poisson regressions, adjusting for age, comorbidities, and ST-elevation. We used Royston-Parmar models for long-term outcomes (all-cause and cardiovascular mortality, incident cardiovascular events), adjusting for age, comorbidities, and secondary prevention. Of a total 47 063 MI patients, 15 776 (33.5%) were women. Median (inter-quartile range) age was 66 (57, 73) years. Compared to men, women were older and more comorbid, but were less likely to undergo percutaneous coronary intervention [risk ratio (95% confidence interval) - 0.87 (0.86 - 0.89)] or receive secondary prevention at discharge [0.94 (0.93-0.95)]. No in-hospital mortality difference was observed between sexes [1.06 (0.99-1.13) after adjustment]. Over a median follow-up of 8.2 (6.7, 10.1) years, women had higher crude rates of adverse outcomes. After full adjustment, this translated into a lower risk for women compared to men of all-cause mortality [hazard ratio, 0.92 (0.89-0.95)], cardiovascular mortality [0.82 (0.78-0.87)], and cardiovascular events [0.92 (0.88-0.95)]. The female survival advantage seen in general population controls was attenuated in MI patients.</p><p><strong>Conclusion: </strong>Women were undertreated compared to men after MI. Their survival and outcome benefits may be improved further. Poor outcomes in men despite better receipt of secondary prevention require further attention.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142727360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal trend and attributable risk factors of cardiovascular diseases burden for adults 55 years and older in 204 countries/territories from 1990 to 2021: an analysis for the Global Burden of Disease Study 2021.","authors":"Ming-Si Wang, Jing-Wen Deng, Wan-Yue Geng, Rui Zheng, Hui-Lin Xu, Ying Dong, Wei-Dong Huang, Yi-Lan Li","doi":"10.1093/eurjpc/zwae384","DOIUrl":"https://doi.org/10.1093/eurjpc/zwae384","url":null,"abstract":"<p><strong>Aims: </strong>The aging global population and overall population growth have significantly increased the burden of cardiovascular diseases (CVDs). This study aims to examine global temporal trends in the incidence, disability-adjusted life years (DALY), and mortality rates of both overall and type-specific CVDs among adults aged 55 and older from 1990 to 2021, with a focus on identifying changes over time, regional disparities, and the key risk factors contributing to this burden.</p><p><strong>Methods and results: </strong>We analyzed data from the Global Burden of Disease (GBD) Study 2021, covering 204 countries and territories. Trends in age-standardized rates of incidence, DALY, and mortality for both overall and specific types of CVDs were assessed, alongside the impact of key risk factors. Between 1990 and 2021, global age-standardized incidence, DALY, and mortality rates showed a declining trend, with estimated annual percentage changes (EAPCs) of -0.39, -1.30, and -1.11, respectively. However, due to overall population growth and aging, the absolute number of CVD cases continued to rise. Regions with high-middle Socio-demographic Index (SDI) exhibited the highest incidence and mortality rates, while high SDI regions saw the greatest declines. Men had higher age-standardized rates of CVDs incidence, DALY, and mortality compared to women. The burden increased with age, with the oldest age groups (80+ years) showing the highest rates. High systolic blood pressure was the leading modifiable risk factor, contributing to more than half of the CVD-related DALY globally. Other major risk factors included high low-density lipoprotein cholesterol, smoking, and ambient particulate matter pollution.</p><p><strong>Conclusions: </strong>While age-standardized rates of CVD incidence, DALY, and mortality have declined over the past three decades, the total burden of CVDs continues to rise due to population aging and growth. These findings highlight the need for targeted prevention strategies in regions with high CVD burden, particularly those with lower socioeconomic status.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142727362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between folate deficiency and hypertension: evidence from an observational and Mendelian randomization study.","authors":"Yanyu Zhang, Darui Gao, Jie Liang, Mengmeng Ji, Wenya Zhang, Yang Pan, Fanfan Zheng, Wuxiang Xie","doi":"10.1093/eurjpc/zwae386","DOIUrl":"https://doi.org/10.1093/eurjpc/zwae386","url":null,"abstract":"<p><strong>Aims: </strong>Although folate intake might affect hypertension risk, evidence about the risk of hypertension according to an individual's folate deficiency status is scarce. Therefore, we aimed to investigate the relationship between folate deficiency and hypertension, and their causal associations.</p><p><strong>Methods and results: </strong>A cross-sectional and prospective cohort study were performed in the UK Biobank (UKB) to investigate the associations between folate deficiency and hypertension prevalence and incidence, using logistic regression and Cox proportional hazard regression, respectively. Subsequently, we conducted one-sample Mendelian randomization (MR) with individual-level data from the UKB to further validate their causal associations. Finally, two-sample MR analyses were applied using summary-level data to further assess the causal relationships of serum folate with blood pressure (BP) and hypertension. In a total of up to 219,089 participants free of hypertension at enrollment, 17,670 participants developed hypertension after a median 12.8 years of follow-up. Compared with participants without folate deficiency, those with folate deficiency had a higher risk of hypertension (HR=1.42, 95% CI=1.24-1.63). One-sample MR analysis in the UKB provided supportive evidence for a causal effect of folate deficiency on hypertension risk (OR for the highest quantile=1.07, 95% CI=1.04-1.10, Ptrend<0.001). Furthermore, two-sample MR also supported a protective effect of higher levels of serum folate on BP (For systolic BP: β =-2.313, 95% CI=-3.532, -1.094; for diastolic BP: β = -1.648, 95% CI= -3.085, -0.211) and hypertension (β =-0.049, 95% CI=-0.069, -0.029).</p><p><strong>Conclusions: </strong>Observational and genetically determined folate deficiency were associated with hypertension, suggesting that folate deficiency might be a causal risk factor for hypertension.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142727352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Modifiable Lifestyle Risk Factors with High-Sensitivity Troponin T and I Concentrations and Clinical Outcomes.","authors":"Benjamin Bay, Luise Pieper, Alina Goßling, Kevin Kaatze, Caroline Kellner, Natalie Arnold, Christopher Blaum, Julia Rohde, Lukas Köster, Thiess Lorenz, Tanja Zeller, Stefan Blankenberg, Christoph Waldeyer, Fabian J Brunner","doi":"10.1093/eurjpc/zwae374","DOIUrl":"https://doi.org/10.1093/eurjpc/zwae374","url":null,"abstract":"<p><strong>Aims: </strong>We aimed to investigate the association between the burden of modifiable lifestyle risk factors (modLRF) with high-sensitivity cardiac troponins T and I (hsTnT/I) and clinical outcomes in a contemporary cohort.</p><p><strong>Methods: </strong>Patients undergoing coronary angiography with available hsTnT/I concentrations and information about modLRF were included in the current single-centre study. The modLRF investigated were overweight, lack of physical activity, poor adherence to a Mediterranean diet and current smoking. To evaluate the impact of modLRF on hsTnT/I levels, a linear regression model was used. A Cox regression analysis was computed to investigate the association of hsTnT/I levels with clinical outcomes, stratified by the burden of modLRF, and a C-Index was calculated to investigate the additive predictive benefit of the integration of hsTn on top of a base model containing modLRF only. Outcomes of interest were all-cause mortality and major adverse cardiovascular events (MACE).</p><p><strong>Results: </strong>In the overall study population of n=1,716 patients median troponin levels were 15.0 ng/l (IQR 8.0, 29.0) and 7.6 ng/l (IQR 3.3, 18.6) for hsTnT and I, respectively. An increasing number of modLRF was independently associated with elevated hsTnT and I concentrations. Moreover, hsTnT and hsTnI were independently associated with all-cause mortality in patients with 1-2 and ≥3 modLRF, and an incremental value of the integration of hsTnT and hsTnI was noted, especially in the prediction of all-cause mortality was noted. Lastly, an independent association of hsTnI with MACE was documented in patients with 1-2 modLRF, which was not the case for hsTnT.</p><p><strong>Conclusion: </strong>Increasing numbers of modLRF are associated with elevated concentrations of hsTnT and I, whilst the predictive capability of troponins varied according to the presence of modLRF. Further prospective studies are needed to investigate, whether targeting modLRF might result in lower hsTn concentrations and improved outcomes.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142715787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aortic Dimension in Elite Athletes: Updated Systematic Review and Meta-Analysis.","authors":"Andreina Carbone, Emanuele Monda, Francesco Ferrara, Monica Franzese, Roberta Bottino, Valentina Russo, Chiara Cirillo, Salvatore Rega, Antonio Cittadini, Antonio Pelliccia, Giuseppe Limongelli, Eduardo Bossone","doi":"10.1093/eurjpc/zwae385","DOIUrl":"https://doi.org/10.1093/eurjpc/zwae385","url":null,"abstract":"<p><strong>Aims: </strong>To assess the presence and the extent of an \"aortic remodeling\" in elite athletes.</p><p><strong>Methods: </strong>A systematic review and meta-analysis of literature were conducted for studies (1981-2024) reporting echocardiographic aortic diameters of elite athletes compared to non-athlete healthy controls. Among the 5,494 studies retrieved, 21 (9,464 elite athletes vs. 2,637 non-athlete controls) fulfilled all eligibility criteria. Data were aggregated using a random effects model for estimating the pooled risk ratio and mean difference.</p><p><strong>Results: </strong>Absolute aortic diameters at the sinus of Valsalva (AoSV) were higher in overall elite athletes compared to non-athlete healthy controls (mean difference [MD] 1.69 [95% CI 1.01-2.37] mm; p <0.001) and if stratified to sex. This difference was maintained if AoSV was indexed to height (AoSV/h) (MD 0.04 [95% CI -0.00-0.08] mm/m; ES 2.18 [95% CI 1.10-3.26]; p<0.001). The analysis of AoSV/h according to sex was not performed for the paucity of studies. However, when indexed to body surface area (AoSV/BSA), no differences were found between the two groups (MD 0.04 [95% CI -0.25-0.34] mm/m2; p = 0.880), also according to sex. Above findings were not influenced by age.</p><p><strong>Conclusions: </strong>Absolute AoSV was mildly larger in athletes compared to non-athlete healthy controls, even when indexed to height. However, no differences were evident when indexed by BSA, irrespective of sex, type of sport and age. Therefore, assessment of the aortic size in elite athletes should consider the proper normalization in order to avoid misdiagnosis of aortopathies.</p><p><strong>Prospero registry id: </strong>CRD42024561255.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142727351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sodium-glucose cotransporter-2 inhibitors and clinical outcomes in patients with hypertrophic cardiomyopathy and diabetes: A population-based cohort study.","authors":"Mi-Hyang Jung, Jung Sun Cho, So-Young Lee, Jong-Chan Youn, Young Choi, Woo-Baek Chung, Jungkuk Lee, Dongwoo Kang, Woojin Kwon, Tae-Seok Kim, Sang-Hyun Ihm, Hae Ok Jung","doi":"10.1093/eurjpc/zwae345","DOIUrl":"https://doi.org/10.1093/eurjpc/zwae345","url":null,"abstract":"<p><strong>Aims: </strong>Hypertrophic cardiomyopathy (HCM) is associated with a significant risk of arrhythmia and heart failure (HF), yet treatment options for patients with HCM have remained limited. We aimed to investigate the relationship between sodium-glucose cotransporter-2 inhibitor (SGLT2i) use and clinical outcomes among patients with concurrent HCM and diabetes in real-world settings.</p><p><strong>Methods and results: </strong>Using the Korean National Health Insurance Service database, we identified patients with a confirmed diagnosis of HCM and prescriptions for antidiabetic drugs from 2018 to 2022. After propensity matching, we compared 2063 patients who received SGLT2i with 2063 patients who did not for clinical outcomes. The primary outcome was a composite of all-cause death and HF hospitalization. Secondary outcomes included individual outcomes of all-cause death, HF hospitalization, sudden cardiac death, and ischaemic stroke. During a median follow-up period of 3.1 years, patients with HCM on SGLT2i had a significantly lower risk of the primary outcome [hazard ratio (HR) 0.76, 95% confidence interval (CI) 0.67-0.86]. Specifically, SGLT2i use was associated with reduced all-cause mortality (HR 0.56, 95% CI 0.46-0.68) and fewer HF hospitalizations (HR 0.82, 95% CI 0.72-0.94). Additionally, SGLT2i use was linked to a decreased risk of sudden cardiac death (HR 0.50, 95% CI 0.33-0.77) and ischaemic stroke (HR 0.74, 95% CI 0.62-0.88). Subgroup analyses by age, sex, and atrial fibrillation did not reveal any significant interactions.</p><p><strong>Conclusion: </strong>The use of SGLT2i was associated with a decreased risk of adverse clinical outcomes among patients with HCM with concurrent diabetes on antidiabetic drugs.</p><p><strong>Lay summary: </strong>This population-based cohort study examined the association between sodium-glucose cotransporter-2 inhibitors (SGLT2is) and clinical outcomes in patients with hypertrophic cardiomyopathy (HCM) and diabetes. Patients with HCM and diabetes who used SGLT2i had a significantly lower risk of all-cause death and heart failure hospitalization compared with those who did not use SGLT2i.These associations were consistent across various subgroups, including sex, age, atrial fibrillation, and income levels.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142686306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating epicardial fat and heart rate recovery in adults with metabolic risk factors.","authors":"Gaetano Santulli, Leonardo Bencivenga, Giuseppe Rengo, Germano Guerra, Pasquale Mone, Klara Komici","doi":"10.1093/eurjpc/zwae380","DOIUrl":"https://doi.org/10.1093/eurjpc/zwae380","url":null,"abstract":"","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142686363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nonobese young females with PCOS are at high risk for long-term cardiovascular disease.","authors":"Xingpig Zhao, Jie Wang, Dan Sun, Dabao Xu, Yao Lu","doi":"10.1093/eurjpc/zwae375","DOIUrl":"https://doi.org/10.1093/eurjpc/zwae375","url":null,"abstract":"<p><strong>Aims: </strong>Whether polycystic ovary syndrome (PCOS) is an independent risk factor for long-term cardiovascular disease (CVD) is unclear, and the risk of CVD in easily overlooked young nonobese PCOS patients is unknown. This study aimed to investigate the associations of PCOS with CVD and identify the management priorities.</p><p><strong>Methods and results: </strong>3864 participants (645 with PCOS) from UK Biobank were recruited from 2006-2010. The cumulative incidences of the CVD were calculated and compared between patients with and without PCOS via the log rank test. Cox proportional risk regression models were used to assess the relationships of PCOS with CVD and the impact of PCOS treatments on CVD risk. Polygenic risk scores and linkage disequilibrium score regression were used to assess the genetic-level associations. Then proteomics subgroup cohort was conducted to explore the significant biomarker involved in the PCOS-CVD associations. Compared with participants without PCOS, participants with PCOS had greater risks of CVD (hazard ratio (HR)=1.77, 95% confidence interval (CI)=1.19-2.65), coronary artery disease (HR=2.27, 95% CI=1.35-3.81) and myocardial infarction (HR=2.08, 95% CI=1.11-3.90) independent of genetic risk, especially for young nonobese PCOS patients (Pfor interaction <0.05). Current commonly used treatments did not affect CVD incidence. Proteomics cohort revealed that discoidin, CUB and LCCL domain-containing protein 2 (DCBLD2) may be specific CVD biomarker for patients with PCOS.</p><p><strong>Conclusion: </strong>Patients with PCOS had an increased risk of CVD, and young nonobese PCOS patients should be prioritized for CVD risk management. These findings support the necessity of clinical surveillance and suggest DCBLD2 as a possible CVD biomarker in females with PCOS.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unveiling the Gender Divide in Heart Failure Prognosis: New Insights from a Comprehensive Meta-Analysis.","authors":"Izabella Uchmanowicz, Hanne Boen","doi":"10.1093/eurjpc/zwae373","DOIUrl":"10.1093/eurjpc/zwae373","url":null,"abstract":"","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of cardiac rehabilitation in patients with left ventricular thrombosis after acute myocardial infarction.","authors":"Alessia Giglio, Gabriella Malfatto, Federico Paoletti, Kevin Bonacina, Silvia Ravaro, Martina De Martin, Gino Seravalle, Gerardina Fratianni, Roberto Chianca, Silvia Castelletti, Gianfranco Parati, Lia Crotti","doi":"10.1093/eurjpc/zwae172","DOIUrl":"10.1093/eurjpc/zwae172","url":null,"abstract":"","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":"1991-1993"},"PeriodicalIF":5.4,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140954734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}